CASI Pharmaceuticals (CASI) Debt to Equity (2021 - 2024)
Historic Debt to Equity for Pharmaceuticals (CASI) over the last 4 years, with Q4 2024 value amounting to $9.93.
- Pharmaceuticals' Debt to Equity fell 9872.97% to $9.93 in Q4 2024 from the same period last year, while for Dec 2024 it was $9.93, marking a year-over-year decrease of 9872.97%. This contributed to the annual value of $9.93 for FY2024, which is 9872.97% down from last year.
- According to the latest figures from Q4 2024, Pharmaceuticals' Debt to Equity is $9.93, which was down 9872.97% from $781.92 recorded in Q4 2023.
- Over the past 5 years, Pharmaceuticals' Debt to Equity peaked at $781.92 during Q4 2023, and registered a low of $0.16 during Q4 2021.
- For the 4-year period, Pharmaceuticals' Debt to Equity averaged around $198.07, with its median value being $5.1 (2022).
- In the last 5 years, Pharmaceuticals' Debt to Equity soared by 29474073.7% in 2023 and then tumbled by 9872.97% in 2024.
- Pharmaceuticals' Debt to Equity (Quarter) stood at $0.16 in 2021, then soared by 69.52% to $0.27 in 2022, then skyrocketed by 294740.74% to $781.92 in 2023, then crashed by 98.73% to $9.93 in 2024.
- Its last three reported values are $9.93 in Q4 2024, $781.92 for Q4 2023, and $0.27 during Q4 2022.